Emily Robb, PharmD

Post-Doctoral Fellow, Medical Information and Medical Affairs Strategy
BioPharmaceuticals, US Medical, AstraZeneca

Poster(s):

• (407) As-needed albuterol–budesonide decreases risk of severe asthma exacerbation in the first three months post-randomization compared to albuterol in patients treated for moderate-to-severe asthma: MANDALA post-hoc analysis
  Wednesday, October 29, 2025